Sort
326,823 grants matching “clinical trial”
Integrated Care for Chronic Pain and Opioid Use Disorder: The IMPOWR Research Center at Montefiore/Einstein (IMPOWR-ME)
$2,465,699Joanna L. Starrels · Albert Einstein College Of Medicine · RM1 · FY2025 · DA
Discovery and validation of novel targets for pharmacotherapy of alcoholism
$2,465,593Markus Heilig · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2010 · AA
Developing a performance-based measure of daily function for screening Hispanic/Latino older adults for Alzheimer's disease risk
$2,465,320Sydney Yoshie Schaefer · Arizona State University-Tempe Campus · RF1 · FY2025 · AG
A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity
$2,465,319Jill Marie Johnsen · University Of Washington · UG3 · FY2024 · HL
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$2,465,296Lorenzo Leggio · National Institute On Drug Abuse · ZIA · FY2024 · DA
Office of the NINR Clinical Director
$2,465,175Suzanne Wingate · National Institute Of Nursing Research · ZID · FY2017 · NR
Discovery, Biology and Risk of Inherited Variants in Breast Cancer
$2,465,094David John Hunter · Harvard School Of Public Health · U19 · FY2011 · CA
Malaria immunology
$2,464,408Susan Pierce · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit
$2,464,363Pablo Tebas · University Of Pennsylvania · UM1 · FY2020 · AI
Research Project 2: Therapeutic Human Monoclonal Antibody Treatments for Filoviruses
$2,464,333James E Crowe · University Of Texas Med Br Galveston · U19 · FY2023 · AI
Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Phase 3 Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial
$2,464,155Parambir Singh Dulai · Northwestern University At Chicago · U01 · FY2025 · DK
ECOG STATISTICAL OFFICE
$2,464,042Dana-Farber Cancer Institute · U10 · FY2001 · CA
Development of Novel Therapies for HIV Infection and AIDS-Related Malignancies
$2,463,925Robert Yarchoan · Clinical Sciences · Z01 · FY2007 · CA
HIV/SIV Database and Analysis Unit
$2,463,763National Institute Of Allergy And Infectious Diseases · Y01 · FY2011 · AI
Mechanisms of Energy Balance and Cancer Prevention
$2,463,212Anne M McTiernan · Fred Hutchinson Cancer Research Center · U54 · FY2007 · CA
Physical Activity to Improve CV Health in Older Women: A Pragmatic Trial
$2,463,010Charles L Kooperberg · Fred Hutchinson Cancer Research Center · R61 · FY2020 · HL
New Approaches to Inducing Cardiac Allograft Tolerance
$2,462,802Joren C Madsen · Massachusetts General Hospital · P01 · FY2021 · HL
UCLA AIDS Prevention and Treatment Clinical Trials Unit
$2,462,528Judith S. Currier · University Of California Los Angeles · U01 · FY2010 · AI
Radiologial Physics Center
$2,462,413David S Followill · University Of Tx Md Anderson Can Ctr · U10 · FY2010 · CA
GENERAL CLINICAL RESEARCH CENTER
$2,462,305University Of Chicago · M01 · FY2000 · RR
Core C: Biosecurity Core
$2,461,801James W. Leduc · University Of Texas Med Br Galveston · UC7 · FY2024 · AI
THE PRIMARY RISK FACTOR LIMITING THE AMOUNT OF TIME AN ASTRONAUT CAN SPEND IN FLIGHT IS THE RISK OF CANCER INDUCTION RESULTING FROM THE UNIQUE RADIATIONS INHERENT TO THE DEEP SPACE ENVIRONMENT. ONE STRATEGY FOR MITIGATING RADIATION INDUCED CARCINOGENESIS IS TO PROVIDE BIOLOGICAL COUNTERMEASURES THAT MITIGATE RADIATION INJURY AND CANCER INDUCTION. TO DATE THE ONLY FDA APPROVED RADIOPROTECTOR IS THE FREE RADICAL SCAVENGER AMIFOSTINE; HOWEVER CONCERNS ABOUT TOXICITY AND REPORTS OF SEVERE ANAPHYLACTIC REACTIONS TO THIS DRUG PREVENT ITS USE IN SPACEFLIGHT. THEREFORE THERE IS A NEED TO DETERMINE AND VALIDATE APPROPRIATE BIOLOGICAL COUNTERMEASURES TO MITIGATE SPACE RADIATION CARCINOGENESIS THEREBY INCREASING THE AMOUNT OF TIME ASTRONAUTS CAN SAFELY SPEND IN SPACE. IN THE PROPOSED STUDIES WE WILL EVALUATE THE RADIO PROTECTIVE POTENTIAL OF GC4419 A NOVEL SUPEROXIDE DISMUTASE MIMETIC DEVELOPED BY GALERA THERAPUTICS (ST. LOUIS MO) IN MITIGATING SPACE RADIATION CARCINOGENESIS. DUE TO ITS EFFICACY IN PHASE 1 CLINICAL TRIALS AND PRE-CLINICAL DATA GENERATED BY OUR GROUP GC4419 IS CURRENTLY BEING FAST TRACKED INTO FDA PHASE II HUMAN CLINICAL TRIALS AS A RADIOPROTECTOR FOR PATIENTS UNDERGOING CHEMORADIATION THERAPY FOR THE TREATMENT OF HEAD AND NECK CANCER. NOT ONLY DOES GC4419 REDUCE THE FREQUENCY OF RADIATION INDUCED ADVERSE EFFECTS PRE-CLINICAL DATA SUGGEST IT HAS POTENT ANTI-CARCINOGENIC AND ANTI-TUMOR EFFECTS AS WELL. THEREFORE GC4419 REPRESENTS A SAFE CLINICALLY TESTED COUNTERMEASURE TO REDUCE RADIATION INJURY. IN THE PROPOSED STUDIES WE WILL EVALUATE THE EFFICACY OF GC4419 IN PREVENTING SPACE RADIATION INDUCED CARCINOGENESIS FOCUSING SPECIFICALLY ON THE LUNG AS A PRIMARY TUMOR SITE.
$2,461,498The University Of Texas Southwestern Medical Center · · FY2020 · National Aeronautics and Space Administration
ECOG Statistical Office Data Management Grant
$2,461,348Robert J Gray · Frontier Sci & Technology Rsch Fdn, Inc · U10 · FY2008 · CA
Mechanisms of Energy Balance and Cancer Prevention
$2,461,328Anne M McTiernan · Fred Hutchinson Cancer Research Center · U54 · FY2009 · CA
Integrated Development of Novel Molecular Markers
$2,461,300Johns Hopkins University · U01 · FY2004 · CA